---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-25-000034"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:02:46.364054+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Travere stockholders approve 4M-share increase in 2018 equity plan at annual meeting

## Summary
- Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000 (71,802,001 votes for).
- Ten directors elected to serve until 2026 annual meeting; all received majority votes with broker non-votes of ~4.4M.
- Advisory vote on named executive officer compensation passed with 71,929,269 votes for.
- Ratification of Ernst & Young as independent auditor for FY2025 approved (79,001,421 votes for).

## SEC filing metadata
- accession: 0001438533-25-000034
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000034/0001438533-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853325000034/tvtx-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-25-000034
- JSON: https://secwatch.observer/filing/0001438533-25-000034.json
- Plain text: https://secwatch.observer/filing/0001438533-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.